Group 1 - Pfizer Inc. announced that the U.S. FDA accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI, expanding its indication to treat hemophilia A or B patients aged 6 years and older with inhibitors, and pediatric patients with hemophilia A or B without inhibitors [1][2] - The FDA set a Prescription Drug User Fee Act action date for HYMPAVZI in Q2 2026, which, if approved, would offer a once-weekly subcutaneous injection for bleed protection without the need for routine lab monitoring [2] - Pfizer launched the TrumpRx program to make over 30 innovative medicines more accessible and affordable for Americans, providing significant discounts off list prices as part of a broader agreement with the U.S. government [3] Group 2 - Pfizer Inc. is a global biopharmaceutical company focused on the development, manufacturing, and marketing of biopharmaceutical products, aiming to advance wellness and treatment in developing and emerging markets [4]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified class period, alleging misleading statements regarding clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Ultragenyx shares from August 3, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations - The complaint claims that Ultragenyx misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Ultragenyx's share price fell from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, representing a decline of over 42% in a single day [3]. Group 3: Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, focusing on treatments for rare diseases [2].

Core Insights - Stonegate Capital Partners has initiated coverage on AB Science S.A., focusing on its late-stage biotech asset, masitinib, which is an oral, selective tyrosine kinase inhibitor aimed at modulating maladaptive neuroinflammation [1] Company Overview - AB Science is advancing masitinib as an add-on therapy for conditions such as ALS (Amyotrophic Lateral Sclerosis), progressive MS (Multiple Sclerosis), and Alzheimer's Disease (AD) [1] - The company is also developing AB8939 for Acute Myeloid Leukemia (AML), indicating a diverse pipeline [1] Clinical Development - The ALS program is supported by prior Phase 2b/3 data, enhancing confidence in its efficacy [6] - For progressive MS, a Phase 3 trial has been authorized in the US and 12 EU countries, with approximately 94 sites initiating the study [6] - Financing for these trials is supported by grants, indicating a solid financial backing for ongoing research [6]

Core Insights - Sanofi has completed the acquisition of Dynavax Technologies Corporation, enhancing its portfolio in adult immunization with Dynavax's hepatitis B vaccine HEPLISAV-B and shingles vaccine candidate Z-1018 [1][2] Acquisition Details - The tender offer for Dynavax's common stock expired on February 9, 2026, and all conditions were satisfied, leading to Sanofi's acceptance of the shares [3] - The acquisition was finalized through a merger, with Dynavax becoming a wholly owned subsidiary of Sanofi, and shares not tendered in the offer will receive $15.50 per share in cash [4] Strategic Implications - This acquisition strengthens Sanofi's commercial reach and development capabilities in the vaccine market, positioning the company for growth in adult immunization [2]

Core Viewpoint - Day One Biopharmaceuticals is set to report its financial results and corporate progress for Q4 and full-year 2025 on February 24, 2026, highlighting its commitment to developing targeted therapies for life-threatening diseases, particularly in pediatric cancer [1]. Group 1: Company Overview - Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company focused on addressing the unmet needs in pediatric cancer treatment [3]. - The company aims to redefine cancer drug development and improve outcomes for patients of all ages from the moment of diagnosis [3]. Group 2: Pipeline and Development - Day One's pipeline includes tovorafenib (OJEMDA™), DAY301, and Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate targeting the B7-H4 protein, currently in clinical development for adenoid cystic carcinoma (ACC) [4]. - The recent acquisition of Mersana Therapeutics enhances Day One's capabilities in developing targeted cancer treatments [4]. Group 3: Communication and Accessibility - A live conference call and webcast will be available for stakeholders to access financial results and corporate updates [2]. - An archived version of the webcast will be accessible for 30 days post-event, ensuring continued engagement with investors and the public [2].

Core Insights - Hoth Therapeutics announced positive preclinical results for its HT-VA GDNF treatment, showing superior efficacy over semaglutide in weight loss, glucose control, and liver health in obesity models [1] Study Design and Results - The study was conducted at the Srinivasan Lab with support from the Veterans Administration, using CF-1 mice to model human obesity over a 12-week period [1] - GDNF reduced liver weight by 20-30% and prevented adipose tissue accumulation in female mice, outperforming semaglutide [1] - GDNF fully normalized fasting glucose levels and improved glucose response, showing broader metabolic benefits in both female and male models [1] - In female mice on a high-fat diet, GDNF reduced weight gain by 10-15%, leading to a plateau in weight, unlike semaglutide which had no significant impact [1] Market Potential - GDNF's differentiated mechanism could address limitations of current GLP-1 agonists, such as gastrointestinal side effects and muscle loss, positioning it as a potential gamechanger in the $200 billion obesity market [1] - With obesity affecting over 1 billion people globally and MASLD impacting up to 30% of adults, GDNF's multi-faceted benefits could revolutionize treatment paradigms [1] Future Plans - Hoth plans to accelerate GDNF toward IND-enabling studies, targeting clinical trials in 2027 [1] - The GDNF program is part of a robust pipeline that includes HT-001 for cancer-related skin toxicities, HT-KIT for mast cell cancers, and HT-ALZ for Alzheimer's [1]

AGOURA HILLS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and CNS-related diseases, today provided an update on key development progress achieved during 2025 and outlined its strategic direction as the Company enters 2026 with continued momentum across its pipeline. 2025: Continued Execution Across a Late-Stage, Diversified Pipeline Oncotelic trans ...

Core Viewpoint - Aardvark Therapeutics has received IRB approval for an amended protocol in its Phase 3 HERO trial, allowing participation of children aged 7 and older with Prader-Willi Syndrome (PWS) in the United States, aiming to enhance access and capture the potential impact of ARD-101 on hyperphagia in this population [1][2][3] Group 1: Trial Details - The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled study assessing ARD-101 for hyperphagia in PWS patients, with plans to enroll 90 patients across multiple countries including the U.S., Australia, Canada, the UK, and South Korea [4] - The primary endpoint of the trial is the change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score from baseline to Week 12, with secondary measures including changes in Caregiver Global Impression of Severity (CaGI-S) and Clinical Global Impression of Severity (CGI-S) scores [4] Group 2: Drug Information - ARD-101 is a gut-restricted small molecule agonist targeting specific taste receptors, stimulating the release of gut-peptide hormones like GLP-1 and cholecystokinin (CCK) to mediate hunger [5] - The drug has shown potential in reducing hunger both alone and in combination with existing GLP-1 therapies, and has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for PWS [5][6] Group 3: Company Overview - Aardvark Therapeutics is focused on developing small-molecule therapeutics aimed at suppressing hunger for the treatment of PWS and other metabolic diseases, with ARD-101 being the lead compound in Phase 3 clinical development [7] - The company is also working on ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, through two separate Phase 2 trials to address limitations of current GLP-1 therapies [8]

Core Insights - OKYO Pharma Limited has appointed Dr. Flavio Mantelli as Chief Medical Officer, who has extensive experience in ocular surface drug development and previously led the successful launch of Oxervate® [1][2][4] Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with shares traded on the Nasdaq Capital Market [14] - The company recently completed a successful Phase 2 trial of its drug urcosimod for NCP and plans to initiate a Phase 2b/3 study involving approximately 150 subjects in the first half of 2026 [14] Leadership and Strategy - Dr. Mantelli will oversee the clinical development strategy for urcosimod, aiming to advance it through planned clinical trials and leverage its FDA Fast Track designation [3][12] - The appointment of Dr. Mantelli follows the recent hiring of CEO Robert Dempsey, strengthening the leadership team in ophthalmology [4][12] Product Development - Urcosimod is a lipid-conjugated chemerin peptide agonist that has shown anti-inflammatory and pain-reducing effects in preclinical models for dry eye disease and neuropathic corneal pain [9] - There are currently no FDA-approved therapies specifically for NCP, highlighting the unmet medical need that urcosimod aims to address [8] Market Context - Neuropathic corneal pain is a chronic condition characterized by severe eye pain and sensitivity, often resulting from damage to corneal sensory nerves, and is inadequately treated with existing medications [8]

Core Insights - ARS Pharmaceuticals is showcasing the clinical advancements and real-world usability of neffy, a needle-free epinephrine delivery system, at the 2026 AAAAI Annual Scientific Meeting [1][2] - The nasal epinephrine has a longer shelf life compared to auto-injectors, leading to a more affordable price point [1] - Patient preference for the nasal option increased by over 25% due to the aversion to needle-based administration [1] Group 1: Clinical Presentations - Five poster presentations and one healthcare professional case report will focus on neffy, highlighting health-economic analyses, patient preference research, and pharmacokinetic comparisons with injectable epinephrine [1][2] - The presentations will demonstrate that neffy 2 mg exposure is comparable to 0.5 mg intramuscular injection, indicating potential cost-effectiveness and patient preference [2] Group 2: Poster Presentation Details - The first poster will discuss the societal value of nasal epinephrine due to needle aversion [3] - The second poster will compare the pharmacokinetics and pharmacodynamics of nasal spray and intramuscular injection [3] - The third poster will focus on treatment preferences between nasal epinephrine and autoinjectors among food-allergic patients [3][4] - Additional posters will address the importance of characteristics of epinephrine treatments and treatment adherence related to nasal versus autoinjector options [4] Group 3: HCP Case Report and Partner Presentations - A healthcare professional case report will evaluate the effectiveness of intranasal epinephrine in routine allergy practice [5] - Late-breaking partner presentations will explore device portability and user preferences between epinephrine autoinjectors and nasal delivery systems [6]